Goldman Sachs Assumes Spring Works Therapeutics (SWTX) at Buy
Tweet Send to a Friend
Goldman Sachs analyst Corinne Jenkins assumes coverage on Spring Works Therapeutics (NASDAQ: SWTX) with a Buy rating and a price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE